The burden of bleeding in haemophilia: is one bleed too many?
about
Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from thTreatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXHemophilia Care in the Pediatric Age.Management of hemophilia in Korea: the past, present, and future.BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BPain and pain management in haemophilia.Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Individualizing prophylaxis in hemophilia: a review.Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.Classification and regression tree analysis vs. multivariable linear and logistic regression methods as statistical tools for studying haemophilia.Differential effects of bleeds on the development of arthropathy - basic and applied issues.Understanding adherence to treatment and physical activity in children with hemophilia: The role of psychosocial factors.Surgical procedures in patients with haemophilic arthropathy of the ankle.Personalized prophylaxis in people with hemophilia A: challenges and achievements.Determining the health-related quality of life in individuals with haemophilia in developing economies: results from the Brazilian population.Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia.Health economic models in hemophilia A and utility assumptions from a clinician's perspective.Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT.Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.Pinpointing clinical phenotypes - Is there evidence to support the use of a simple scoring system to define a milder bleeding phenotype in severe haemophilia A?Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.An innovative outcome-based care and procurement model of hemophilia management.Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
P2860
Q28075208-DCBC77C4-DE30-4774-8C22-52C466CB23A3Q31115372-69CD4C12-6BF3-4C66-B88A-C3349C93E8C2Q33608230-6BA1A828-CCAE-4828-BBFA-462A69BE2FEDQ33737259-690777B7-1692-4831-8EA3-8FCB692E1893Q34302456-F2D2CAF5-72FB-4BB2-A352-DFAD33DF2C90Q34348566-D386D904-A4F1-4DDF-8266-4FA29B8CF31DQ37381096-0F64627A-5BFC-412C-AFEA-2176AA721DD9Q37609087-F4EF21EC-1C45-40D8-B3F9-B949AC952BB2Q38323857-08045BCD-BA4C-4A98-A9EA-327E1F250489Q38546790-8915FCA7-A092-4FA6-94F6-40662076481BQ38561909-F08D80A9-10E3-4178-8721-26F26496C392Q38692376-BF33543B-4A12-478B-A6DC-3B0D47EB40D1Q38772995-560832DE-73FC-4031-8571-78F8D629423FQ38793760-3BFF2470-885B-46C6-B2CC-07DB58B80B8FQ38997467-6FE9F912-BC2B-4F84-9767-9A1E6DC777BAQ39120920-F7447016-CEE1-4908-95CC-D1174B7C3D1AQ39666092-491179F4-7A4B-4411-8E4A-68DF86A9735AQ40445467-A1CCECC4-E981-4B97-80E0-2A3A3941C4CBQ40938357-ED903AE1-E6CF-4117-ACCC-F50B3FD650E2Q42695890-104D630C-D0DD-4D9A-A78C-25F3403709CCQ44875495-F0EBAB0E-95C5-4E06-B7D0-44E1D0DE9BB2Q45855670-51026245-FCF4-4509-BD49-EA3AD60137CCQ45868474-EE6E4660-5FA6-4395-8141-D5586584A209Q45868489-3C41A5BF-5E53-43C3-B59C-482C36F99001Q45869111-B4C900C4-0589-4926-8BF7-E2868D365430Q45869681-2ABEC532-E7CB-4291-8AC7-71F55D62756BQ45871094-1023F214-5ABE-421C-8B27-7AF2C3B95199Q45872664-3D4E6907-4564-45BB-AFC9-FE190C9739C4Q45884983-2984BC85-8F9C-466B-B632-1ACDCBE58176Q45885955-B2FF0B85-D01B-41E8-9AA0-A071E9DCAEDBQ58583115-DD1D3962-28BE-4C94-B000-FC5D4A47FD7E
P2860
The burden of bleeding in haemophilia: is one bleed too many?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The burden of bleeding in haemophilia: is one bleed too many?
@en
type
label
The burden of bleeding in haemophilia: is one bleed too many?
@en
prefLabel
The burden of bleeding in haemophilia: is one bleed too many?
@en
P2093
P2860
P356
P1433
P1476
The burden of bleeding in haemophilia: is one bleed too many?
@en
P2093
A Gringeri
A Reininger
B Ewenstein
P2860
P304
P356
10.1111/HAE.12375
P577
2014-01-29T00:00:00Z